SteinbergD.Studies on the mechanism of action of probucol. Am J Cardiol1986; 57: 16H–21H.
2.
SchwartzCJ. Introduction—the probucol experience: A review of the past and a look at the future. Am J Cardiol1988; 62: 1B–5B.
3.
GlueckCJ. Colestipol and probucol: Treatment of primary and familial hypercholesterolemia and amelioration of atherosclerosis. Ann Intern Med1982; 96: 475–82.
CohenL.MorganJ.Effectiveness of individualized long-term therapy with niacin and probucol in reduction of serum cholesterol. J Fam Pract1988; 26: 145–50.
6.
KuoPTWilsonACKostisJB, Effects of combined probucol-colestipol treatment for familial hypercholesterolemia and coronary artery disease. Am J Cardiol1986; 57: 43H–8H.
7.
DujovneCAKrehbielP.ChernoffSB. Controlled studies of the efficacy and safety of combined probucol-colestipol therapy. Am J Cardiol1986; 57: 36H–42H.
8.
MurphyBF. Probucol (Lorelco) in treatment of hyperlipemia. JAMA1977; 238: 2537–8.
9.
TroendleG.GueriguianJ.SobelS., Probucol and the QT interval (letter). Lancet1982; 1: 1179.
10.
BoudoulasH.BushCASchallSF, Prolonged electrical systole and QT/QS2 secondary to coronary artery disease. Am J Cardiol1985; 55: 915–9.
11.
DujovneCAAtkinsF.WongB., Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur J Clin Pharmacol1984; 26: 735–9.
12.
RomicsL.LittmannL.LaszloZ., The effects of probucol on QT/QS2 relation and systolic time intervals. Int J Cardiol1988; 19: 303–8.
13.
GordonT.CastelliWPHjortlandMC, High density lipoproteins as a protective factor against coronary heart disease. The Framingham Study. Am J Med1977; 62: 707–14.
14.
KannelWB. High density lipoproteins: Epidemiologic profile and risks of coronary artery disease. Am J Cardiol1983; 52: 9B–12B.
15.
KeysA.KarvonenMJPunsarS., HDL serum cholesterol and 24-year mortality of men in Finland. Int J Epidemiol1984; 13: 428–35.
16.
PocockSJShaperAGPhillipsAN, High density lipoprotein cholesterol is not a major risk factor for ischaemic heart disease in British men. Br Med J1986; 292: 515–9.
17.
Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA1984; 251: 351–64.
18.
Lipid Research Clinics Program. The Lipid Research Clinics coronary primary prevention trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA1984; 251: 365–74.
19.
BrensikeJFLevyRIKelseySF, Effects of therapy with cholestyramine on progression of coronary arteriosclerosis. Results of the NHLBI type II coronary intervention study. Circulation1984; 69: 313–24.
20.
LevyRIBrensikeJFEpsteinSE, The influence of changes in lipid values induced by cholestyramine and diet on progression of coronary artery disease. Results of the NHLBI type II coronary intervention study. Circulation1984; 69: 325–37.
21.
FrickMHEloO.HaapaK.Helsinki heart study: Primary prevention trial with gemfibrozil in middle aged men with dyslipidemia. N Engl J Med1987; 317: 1237–45.
22.
GwynneJT. Lipoprotein structure and metabolism. Consultant1988; 28 (suppl): 6–14.
23.
BrownMSGoldsteinJL. A receptor-mediated pathway for cholesterol homeostasis. Science1986; 232: 34–47.
24.
GwynneJT. Probucol, high density lipoprotein metabolism and reverse cholesterol transport. Am J Cardiol1988; 62: 48B–51B.
25.
YamamotoA.MatsuzawaY.YokoyamaS., Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol1986; 57: 29H–35H.
26.
MatsuzawaY.YamashitaS.FunahashiT., Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyper HDL2 cholesterolemia with abnormal cholesterol ester transfer. Am J Cardiol1988; 62: 66B–72B.
27.
WisslerRWVesselinovitchD.Combined effects of cholestyramine and probucol on regression of atherosclerosis in rhesus monkey aortas. Appl Pathol1983; 1: 89–96.
28.
WalldiusG.CarlsonLAEriksonU., Development of femoral atherosclerosis in hypercholesterolemia patients during treatment with cholestyramine and probucol/placebo: Probucol quantitative regression Swedish trial (PQRST): A status report. Am J Cardiol1988; 62: 37B–43B.
29.
EriksonU.NilssonS.StenportG.Probucol quantitative regression Swedish trial: New angiographic technique to measure atheroma volume of the femoral artery. Am J Cardiol1988; 62: 44B–7B.
30.
GoldbergRBMendezA.Probucol enhances cholesterol efflux from cultured human skin fibroblasts. Am J Cardiol1988; 62: 57B–9B.
31.
SirtoriCRSirtoriM.CalabresiL., Changes in high density lipoprotein subfraction distribution and increased cholesteryl ester transfer after probucol. Am J Cardiol1988; 62: 73B–6B.
32.
AburataniH.MatsumotoA.KodamaT., Increased levels of messenger ribonucleic acid for apolipoprotein E in the spleen of probucol-treated rabbits. Am J Cardiol1988; 62: 60B–5B.
33.
SteinbergD.ParthasarathyS.CarewTE, Beyond cholesterol: Modifications of low density lipoprotein that increase its atherogenicity. N Engl J Med1989; 320: 915–24.
34.
ParthasarathyS.YoungSGWitztumJL, Probucol inhibits oxidative modification of low density lipoproteins. J Clin Invest1986; 77: 641–4.
35.
YamamotoA.HaraH.TakaichiS., Effect of probucol on macrophages, leading to regression of xanthomas and atheromatous vascular lesions. Am J Cardiol1988; 62: 31B–6B.
36.
CarewTESchwenkeDCSteinbergD.Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci USA1987; 84: 7725–9.
37.
KitaT.NaganoY.YokodeM., Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA1987; 84: 5928–31.
38.
DrashALRudertWABorquayeS., Effect of probucol on development of diabetes mellitus in BB rats. Am J Cardiol1988; 62: 27B–30B.
39.
ChisholmGCMorelDW. Lipoprotein oxidation and cytotoxicity: Effect of probucol on streptozotocin treated rats. Am J Cardiol1988; 62: 20B–6B.
40.
RussellG.Bulimia nervosa: An ominous variant of anorexia nervosa. Psychol Med1979; 9: 429–48.
41.
BondWSCrabbeS.SandersMC. Pharmacotherapy of eating disorders: A critical review. Drug Intell Clin Pharm1986; 20: 659–65.
42.
MitchellJEHatsukamiD.PyleRLEckertED. The bulimia syndrome: Course of illness and associated problems. Compr Psychiatry1986; 27: 165–70.
43.
MitchellJEDavisL.GoffG.The process of relapse in patients with bulimia. 1nt J Eating Disord1985; 4: 457–63.
44.
WalshBTStewartJWRooseSPGladisM.GlassmanAH. Treatment of bulimia with phenelzine. Arch Gen Psychiatry1984; 41: 1105–9.
45.
JinksMJ. Obesity, anorexia nervosa, bulimia, and other eating disorders. In: HerfindalETGourleyDRHartLL, eds. Clinical pharmacy and therapeutics. Baltimore: Williams & Wilkins, 1988: 669–77.
46.
LippeBM. The physiologic aspects of eating disorders. J Am Acad Child Psychiatry1983; 22: 108–13.
47.
MitchellJEGroatR.A placebo-controlled, double-blind trial of amitriptyline in bulimia. J Clin Psychopharmacol1984; 4: 186–93.
48.
PopeHGHudsonJIJonasJMYurgelun-ToddD.Bulimia treated with imipramine: A placebo-controlled, double-blind controlled study. Int J Eating Disord1987; 6: 29–38.
49.
AgrasWSDoreainB.KirkelyBGArnowB.BachmanJ.Imipramine in the treatment of bulimia: A double-blind controlled study. Int J Eating Disord1987; 6: 29–38.
50.
HughesPLWellsLACunninghamCJIlstrupDM. Treating bulimia with desipramine. Arch Gen Psychiatry1986; 43: 182–6.
51.
BarlowJBBlouinJ.BlouinA.PerezE.Treatment of bulimia with desipramine: A double-blind crossover study. Can J Psychiatry1988; 33: 129–33.
52.
WalshBTGladisM.RooseSPStewartJWStetnerF.GlassmanAH. Phenelzine vs placebo in 50 patients with bulimia. Arch Gen Psychiatry1988; 45: 471–5.
53.
SabineEJYonaceA.FarringtonAJBarrattKHWakelingA.Bulimia nervosa: A placebo controlled double-blind therapeutic trial of mianserin. Br J Clin Pharmacol1983; 15 (suppl): 195S–202S.
54.
PopeHGHudsonJIJonasJMYurgelun-ToddD.Antidepressant treatment of bulimia: A two-year follow-up study. J Clin Psychopharmacol1985; 5: 321–7.
55.
ShopsinB.SoperR.TyrerS.Van Wyck FleetJ.SternW.Bupropion (Wellbutrin)—imipramine study: A single-blind comparison in depressed outpatients. Curr Ther Res1983; 33: 339–61.
56.
ZungW.Review of placebo-controlled trials with bupropion. J Clin Psychiatry1983; 44: 104–14.
57.
RemickR.CamposP.MisriS.MilesJ.Van Wyck FleetJ.A comparison of the safety and efficacy of bupropion HCl and amitriptyline HCl in depressed outpatients. Prog Neuropsychopharmacol1982; 6: 523–7.
58.
Van Wyck FleetJ.ManbergP.MillerL., Overview of clinically significant adverse reactions to bupropion. J Clin Psychiatry1983; 44: 191–6.
59.
CarsonSW. Bupropion, is it here to stay? DICP Ann Pharmacol Ther1989; 23: 704–5.
60.
WalshBTStewartJWWrightL.HarrisonW.RooseSPGlassmanAH. Treatment of bulimia with monoamine oxidase inhibitors. Am J Psychiatry1982; 139: 1629–30.
61.
StewartJWWalshBTWrightL.RooseSPGlassmanAH. An open trial of MAO inhibitors in bulimia. J Clin Psychiatry1984; 45: 217–9.
62.
PopeHGHerridgePLHudsonJIFontaineR.Yurgelun-ToddD.Treatment of bulimia with nomifensine. Am J Psychiatry1986; 143: 371–3.
63.
WoldP.Trazodone in the treatment of bulimia. J Clin Psychiatry1983; 44: 275–6.
64.
PopeHGHudsonJIJonasJM. Antidepressant treatment of bulimia: Preliminary experience and practical recommendations. J Clin Psychopharmacol1983; 3: 274–81.
65.
MitchellPB. The pharmacological management of bulimia nervosa: A critical review. Int J Eating Disord1988; 7: 29–41.
66.
GhaudhuryEBJacobsonED. Prostaglandin cytoprotection of gastric mucosa. Gastroenterology1978; 74: 58–63.
67.
GrayKJEngelmannUHJohnsonEHFishmanLI. Evaluation of misoprostol cytoprotection of the bladder with cyclophosphamide (Cytoxan) therapy. J Urol1986; 136: 497–500.
68.
ShurafaM.ShumakerE.CroninS.Prostaglandin F2-alpha bladder irrigation for control of intractable cyclophosphamide-induced hemorrhagic cystitis. J Urol1987; 137: 1230–1.
69.
MohiuddinJ.PrenticeHGScheyS.BlacklockH.DandonaP.Treatment of cyclophosphamide-induced cystitis with prostaglandin E2 (letter). Ann Intern Med1984; 101: 142.
70.
OstroffEBChenaultOWJrAlum irrigation for the control of massive bladder hemorrhage. J Urol1982; 128: 929–30.
71.
CoxPJ. Cyclophosphamide cystitis—identification of acrolein as the causative agent. Biochem Pharmacol1979; 28: 2045–9.
72.
DrollerMJSaralR.SantosG.Prevention of cyclophosphamide-induced hemorrhagic cystitis. Urology1982; 20: 256–8.
73.
HowsJMMehtaA.WardL., Comparison of mesna with forced diuresis to prevent cyclophosphamide-induced hemorrhagic cystitis in marrow transplantation: A prospective randomized study. Br J Cancer1984; 50: 753–6.
74.
WhittakerJ.FreedS.Effects of formalin on bladder urothelium. J Urol1975; 114: 866–70.
75.
DuckettJWJrPetersPCDonaldsonMH. Severe cyclophosphamide hemorrhagic cystitis controlled with phenol. J Pediatr Surg1973; 8: 55–7.
76.
KumarAPMWrennELJrJayalakshmammaB.ConradL.QuinnP.CoxC.Silver nitrate irrigation to control bladder hemorrhage in children receiving cancer therapy. J Urol1976; 11: 85–6.
77.
El-GehndiMANassarSHToppozadaM.Abdel-RaheemF.Pharmacotherapeutics of prostaglandin E2 and 15(S) 5-methyl prostaglandin F2-alpha in chronic schistosomal bladder ulcer: A clinico-endoscopic study. Prostaglandins1982; 24: 97–104.
